Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 7/20 | 0.44 |
| ▸ | LGALS7; LGALS7B | P47929 | 3/20 | 0.43 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.42 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.42 |
| ▸ | SELP | P16109 | 7/20 | 0.41 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.40 |
| ▸ | MAG | P20916 | 1/20 | 0.39 |
| ▸ | SELE | P16581 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15965623 | 0.91 | LGALS3 (0.39) | LGALS3LGALS7; LGALS7BLGALS1SELPLGALS9 | |
| SCHEMBL15965622 | 0.87 | POLB (0.46) | LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4 | |
| SCHEMBL15965629 | 0.87 | POLB (0.41) | SELPMAGSELE | |
| SCHEMBL15965614 | 0.86 | POLB (0.46) | MAG | |
| SCHEMBL15965620 | 0.85 | POLB (0.47) | MAG | |
| SCHEMBL15965627 | 0.85 | POLB (0.47) | — | |
| SCHEMBL16360943 | 0.84 | LGALS3 (0.51) | LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4 | |
| SCHEMBL16360860 | 0.84 | LGALS3 (0.51) | LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4 | |
| SCHEMBL15965619 | 0.83 | TYMP (0.40) | LGALS3LGALS7; LGALS7BLGALS1LGALS8SELP | |
| SCHEMBL15965625 | 0.82 | POLB (0.44) | MAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140235850-A1 | SYNTHESIS OF HMO CORE STRUCTURES | GLYCOM A/S (DK) | 2014-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235850-A1 | SYNTHESIS OF HMO CORE STRUCTURES | GNE, OGT, GALE | LGALS3 165/4885LGALS7; LGALS7B 64/4885LGALS1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.